A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer

Authors:

Abstract
No abstract available
Funding Information
  • Changzhou Qianhong Biopharmaceuticals Co Ltd.
  • Changzhou LeSun Pharmaceuticals Ltd
  • Australia Government National Health and Medical Research Council (1135682)
  • Commonwealth Government Research Training Program Scholarship

This publication has 39 references indexed in Scilit: